TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg.

TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg.
复制标题

DOI:
10.3389/fphar.2018.00279
复制
发表时间:
2018
影响因子:
5.6
通讯作者:
Li JX
Li JX
中科院分区:
医学2区
文献类型:
--
作者:
Liu JF;Li JX

文献摘要

参考文献

被引文献

相似文献

痕量胺相关受体1(TAAR 1)是TAAR家族中最具特征的成员。TAAR 1在脑中广泛表达,特别是在单胺能系统中。从电生理学和神经化学研究评估的遗传和药理学干预对TAAR 1的影响的证据表明,TAAR 1调节单胺,特别是多巴胺的传输。TAAR 1激动剂抑制药物滥用诱导的多巴胺积累。一般来说,TAAR 1激动剂特异性抑制药物滥用和药物滥用相关行为的奖励和强化作用。TAAR 1的机制的细节仍然难以捉摸;然而,它被认为是通过与D2受体的相互作用来调节的。此外,TAAR 1和D3之间的相互作用等替代细胞机制也可能参与TAAR 1激动剂的作用。TAAR 1在其他药物滥用相关行为中的作用及其神经机制有待进一步研究。总的来说,TAAR 1负调节多巴胺能系统和多巴胺相关行为,TAAR 1激动剂是治疗药物成瘾和复发的有希望的药物疗法。
Trace-amine associated receptor 1 (TAAR1) is the best-characterized member of the family of TAARs. TAAR1 is broadly expressed in the brain, especially within the monoaminergic systems. Evidence from electrophysiological and neurochemical studies evaluating the effects of genetic and pharmacological interventions on TAAR1 revealed that TAAR1 modulates transmission of monoamines, especially dopamine. TAAR1 agonists dampened drugs of abuse-induced dopamine accumulation. In general, TAAR1 agonists specifically inhibited the rewarding and reinforcing effects of drugs of abuse and drug-abuse related behaviors. Details of the mechanism of TAAR1 remain elusive; however, it is thought to be regulated by its interactions with D2 receptors. In addition, the alternative cellular mechanism such as an interaction between TAAR1 and D3 may also participate in the action of TAAR1 agonists. Further studies are required to investigate the role of TAAR1 in other drugs of abuse-related behaviors and the underlying neural mechanisms. Collectively, TAAR1 negatively modulates dopaminergic systems and dopamine-related behaviors and TAAR1 agonists are promising pharmacotherapy to treat drug addiction and relapse.
DOI: 10.1016/j.euroneuro.2015.08.011
发表时间: 2015-11-01
影响因子: 5.6
作者:
Harmeier, Anja;Obermueller, Stefan;Hoener, Marius C.
通讯作者: Hoener, Marius C.
安非他明、3,4-亚甲二氧基甲基苯丙胺、麦角酸二乙酰胺和儿茶酚胺神经递质的代谢物是大鼠微量胺受体的激动剂
DOI: 10.1124/mol.60.6.1181
发表时间: 2001-12-01
影响因子: 3.6
作者:
Bunzow, JR;Sonders, MS;Grandy, DK
通讯作者: Grandy, DK
DOI: 10.1093/ijnp/pyu060
发表时间: 2015-02-01
影响因子: 4.8
作者:
Jing, Li;Zhang, Yanan;Li, Jun-Xu
通讯作者: Li, Jun-Xu
DOI: 10.1016/j.neuropharm.2014.06.011
发表时间: 2014-10
期刊: Neuropharmacology
影响因子: 4.7
作者:
Cisneros IE;Ghorpade A
通讯作者: Ghorpade A
DOI: 10.1016/j.neuropharm.2014.02.007
发表时间: 2014-06-01
期刊: NEUROPHARMACOLOGY
影响因子: 4.7
作者:
Leo, D.;Mus, L.;Gainetdinov, R. R.
通讯作者: Gainetdinov, R. R.